F m Investments LLC Trims Holdings in Soleno Therapeutics, Inc. $SLNO

F m Investments LLC lowered its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 22.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,541 shares of the company’s stock after selling 11,226 shares during the quarter. F m Investments LLC’s holdings in Soleno Therapeutics were worth $3,313,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Board of Administration of Florida Retirement System raised its holdings in Soleno Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 9,057 shares of the company’s stock valued at $759,000 after acquiring an additional 2,427 shares in the last quarter. Atika Capital Management LLC grew its holdings in Soleno Therapeutics by 19.0% during the 2nd quarter. Atika Capital Management LLC now owns 120,500 shares of the company’s stock worth $10,095,000 after acquiring an additional 19,250 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of Soleno Therapeutics in the 2nd quarter worth about $113,000. Russell Investments Group Ltd. increased its position in shares of Soleno Therapeutics by 394,914.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 82,953 shares of the company’s stock worth $6,950,000 after purchasing an additional 82,932 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Soleno Therapeutics by 53.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,103 shares of the company’s stock valued at $344,000 after purchasing an additional 1,426 shares in the last quarter. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

Shares of NASDAQ SLNO opened at $50.46 on Friday. Soleno Therapeutics, Inc. has a 1-year low of $41.50 and a 1-year high of $90.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 15.13 and a quick ratio of 15.01. The business’s fifty day moving average price is $58.31 and its two-hundred day moving average price is $70.12. The firm has a market capitalization of $2.71 billion, a PE ratio of -12.19 and a beta of -2.92.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.39. The firm had revenue of $66.02 million for the quarter, compared to analyst estimates of $47.46 million. On average, research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cowen reiterated a “buy” rating on shares of Soleno Therapeutics in a research note on Thursday, August 7th. Wells Fargo & Company reiterated an “overweight” rating and issued a $106.00 target price (down previously from $123.00) on shares of Soleno Therapeutics in a research report on Wednesday, November 5th. Oppenheimer boosted their price target on Soleno Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. HC Wainwright restated a “buy” rating and set a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a research note on Monday, August 18th. Finally, Wolfe Research initiated coverage on shares of Soleno Therapeutics in a research note on Tuesday, November 18th. They set an “outperform” rating and a $75.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $111.46.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.